Mesoporous silica nanoparticles for breast cancer theranostics: advances in imaging and therapy
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Caestecker KW, Van de Walle GR (2013) The role of BRCA1 in DNA double-strand repair: past and present. Exp Cell Res 319(5):575–587. https://doi.org/10.1016/j.yexcr.2012.11.01310.1016/j.yexcr.2012.11.013 ↗
2. Fradet-Turcotte A, Sitz J, Grapton D, Orthwein A (2016) BRCA2 functions: from DNA repair to replication fork stabilization. Endocr Relat Cancer 23(10):T1–T17. https://doi.org/10.1530/ERC-16-029710.1530/ERC-16-0297 ↗
3. Huber-Keener KJ (2022) Cancer genetics and breast cancer. Best Pract Res Clin Obstet Gynaecol 82:3–11. https://doi.org/10.1016/j.bpobgyn.2022.01.00710.1016/j.bpobgyn.2022.01.007 ↗
4. Key T, Appleby P, Barnes I, Reeves G, Endogenous H (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–16. https://doi.org/10.1093/jnci/94.8.60610.1093/jnci/94.8.606 ↗
5. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D et al (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women’s Health Initiative Randomized Trial. JAMA 289(24):3243–3253. https://doi.org/10.1001/jama.289.24.324310.1001/jama.289.24.3243 ↗
6. Nindrea RD, Aryandono T, Lazuardi L (2017) Breast cancer risk from modifiable and non-modifiable risk factors among women in Southeast Asia: a meta-analysis. Asian Pac J Cancer Prev 18(12):3201–3206. https://doi.org/10.22034/APJCP.2017.18.12.320110.22034/APJCP.2017.18.12.3201 ↗
7. Brody JG, Rudel RA (2003) Environmental pollutants and breast cancer. Environ Health Perspect 111(8):1007–1019. https://doi.org/10.1289/ehp.631010.1289/ehp.6310 ↗
8. Xu B, Li S, Shi R, Liu H (2023) Multifunctional mesoporous silica nanoparticles for biomedical applications. Signal Transduct Target Ther 8(1):43510.1038/s41392-023-01654-7 ↗
9. Zarkesh K, Heidari R, Iranpour P, Azarpira N, Ahmadi F, Mohammadi-Samani S et al (2022) Theranostic hyaluronan coated EDTA modified magnetic mesoporous silica nanoparticles for targeted delivery of cisplatin. Journal of Drug Delivery Science and Technology 77:103903. https://doi.org/10.1016/j.jddst.2022.10390310.1016/j.jddst.2022.103903 ↗
10. Chen F, Hong H, Shi S, Goel S, Valdovinos HF, Hernandez R et al (2014) Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep. 4(5080):5080. https://doi.org/10.1038/srep0508010.1038/srep05080 ↗
11. Laranjeira MS, Ribeiro TP, Magalhaes AI, Silva PC, Monteiro FJ, Santos JAM (2022) Magnetic mesoporous silica nanoparticles as a theranostic approach for breast cancer: loading and release of the poorly soluble drug exemestane. Int J Pharm 619:121711. https://doi.org/10.1016/j.ijpharm.2022.12171110.1016/j.ijpharm.2022.121711 ↗
12. Pires ICB, Shuchi SI, Tostes BVA, Santos D, Burnett WL, Leonce BC et al (2024) Theranostics using MCM-41-based mesoporous silica nanoparticles: integrating magnetic resonance imaging and novel chemotherapy for breast cancer treatment. Int J Mol Sci 25(15):8097. https://doi.org/10.3390/ijms2515809710.3390/ijms25158097 ↗
13. Ilyas S, EMS S, Szymura A, Pes J, Habib S, Florea A et al (2023) Validation of dual-action chemo-radio-labeled nanocarriers with high efficacy against triple-negative breast cancer. ACS Appl Mater Interfaces. 15(42):48963–77. https://doi.org/10.1021/acsami.3c1057910.1021/acsami.3c10579 ↗
14. Gao Q, Xie W, Wang Y, Wang D, Guo Z, Gao F et al (2018) A theranostic nanocomposite system based on radial mesoporous silica hybridized with Fe 3 O 4 nanoparticles for targeted magnetic field responsive chemotherapy of breast cancer. RSC Adv 8(8):4321–432810.1039/C7RA12446E ↗
15. Li T, Geng Y, Zhang H, Wang J, Feng Y, Chen Z et al (2020) A versatile nanoplatform for synergistic chemo-photothermal therapy and multimodal imaging against breast cancer. Expert Opin Drug Deliv 17(5):725–733. https://doi.org/10.1080/17425247.2020.173603310.1080/17425247.2020.1736033 ↗
16. Lei G, Mao C, Yan Y, Zhuang L, Gan B (2021) Ferroptosis, radiotherapy, and combination therapeutic strategies. Protein Cell 12(11):836–857. https://doi.org/10.1007/s13238-021-00841-y10.1007/s13238-021-00841-y ↗
17. Olivieri F, Castaldo R, Cocca M, Gentile G, Lavorgna M (2021) Mesoporous silica nanoparticles as carriers of active agents for smart anticorrosive organic coatings: a critical review. Nanoscale 13(20):9091–911110.1039/D1NR01899J ↗
18. Poonia N, Lather V, Pandita D (2018) Mesoporous silica nanoparticles: a smart nanosystem for management of breast cancer. Drug Discovery Today 23(2):315–33210.1016/j.drudis.2017.10.022 ↗
19. Rani R, Malik P, Dhania S, Mukherjee TK (2023) Recent advances in mesoporous silica nanoparticle-mediated drug delivery for breast cancer treatment. Pharmaceutics 15(1):22710.3390/pharmaceutics15010227 ↗
20. Zhang C, Xie H, Zhang Z, Wen B, Cao H, Bai Y et al (2022) Applications and biocompatibility of mesoporous silica nanocarriers in the field of medicine. Front Pharmacol 13:82979610.3389/fphar.2022.829796 ↗
21. Esmaeili Y, Khavani M, Bigham A, Sanati A, Bidram E, Shariati L et al (2022) Mesoporous silica@ chitosan@ gold nanoparticles as “on/off” optical biosensor and pH-sensitive theranostic platform against cancer. Int J Biol Macromol 202:241–25510.1016/j.ijbiomac.2022.01.063 ↗
22. Garceili Y, Khav V, Ovejero‐Paredes K, Díaz‐García D, Méndez‐Arriaga JM, Prashar S, Filice M, et al. Albumin‐loaded silica nanomaterials functionalized with organotin (IV) agents: theranostic materials against triple‐negative breast cancer. Advanced Therapeutics. 2024:2400114.
23. Chen F, Hong H, Shi S, Goel S, Valdovinos HF, Hernandez R et al (2014) Engineering of hollow mesoporous silica nanoparticles for remarkably enhanced tumor active targeting efficacy. Sci Rep 4(1):1–10
24. Li Y, Li N, Pan W, Yu Z, Yang L, Tang B (2017) Hollow mesoporous silica nanoparticles with tunable structures for controlled drug delivery. ACS Appl Mater Interfaces 9(3):2123–212910.1021/acsami.6b13876 ↗
25. Pérez-Garnes M, Gutiérrez-Salmerón M, Morales V, Chocarro-Calvo A, Sanz R, García-Jiménez C et al (2020) Engineering hollow mesoporous silica nanoparticles to increase cytotoxicity. Mater Sci Eng, C 112:11093510.1016/j.msec.2020.110935 ↗
26. Niu SW, Zhang XJ, Williams GR, Wu JR, Gao F, Fu Z et al (2021) Hollow mesoporous silica nanoparticles gated by chitosan-copper sulfide composites as theranostic agents for the treatment of breast cancer. Acta Biomater 126:408–420. https://doi.org/10.1016/j.actbio.2021.03.02410.1016/j.actbio.2021.03.024 ↗
27. He J, Li C, Ding L, Huang Y, Yin X, Zhang J et al (2019) Tumor targeting strategies of smart fluorescent nanoparticles and their applications in cancer diagnosis and treatment. Adv Mater 31(40):190240910.1002/adma.201902409 ↗
28. Sakhtianchi R, Darvish B, Mirzaie Z, Dorkoosh F, Shanehsazzadeh S, Dinarvand R (2019) Pegylated magnetic mesoporous silica nanoparticles decorated with AS1411 Aptamer as a targeting delivery system for cytotoxic agents. Pharm Dev Technol 24(9):1063–1075. https://doi.org/10.1080/10837450.2019.156967810.1080/10837450.2019.1569678 ↗
29. Akbarzadeh M, Babaei M, Abnous K, Taghdisi SM, Peivandi MT, Ramezani M et al (2019) Hybrid silica-coated Gd-Zn-Cu-In-S/ZnS bimodal quantum dots as an epithelial cell adhesion molecule targeted drug delivery and imaging system. Int J Pharm 570:118645. https://doi.org/10.1016/j.ijpharm.2019.11864510.1016/j.ijpharm.2019.118645 ↗
30. Pascual L, Cerqueira-Coutinho C, Garcia-Fernandez A, de Luis B, Bernardes ES, Albernaz MS et al (2017) MUC1 aptamer-capped mesoporous silica nanoparticles for controlled drug delivery and radio-imaging applications. Nanomedicine 13(8):2495–2505. https://doi.org/10.1016/j.nano.2017.08.00610.1016/j.nano.2017.08.006 ↗
31. Thi TTH, Nguyen TNQ, Hoang DT, Nguyen DH (2019) Functionalized mesoporous silica nanoparticles and biomedical applications. Mater Sci Eng, C 99:631–65610.1016/j.msec.2019.01.129 ↗
32. Siddiqui B, Haq I-u, Al-Dossary AA, Elaissari A, Ahmed N (2022) Exploiting recent trends for the synthesis and surface functionalization of mesoporous silica nanoparticles towards biomedical applications. International Journal of Pharmaceutics: X 4:100116
33. Ovejero Paredes K, Diaz-Garcia D, Garcia-Almodovar V, Lozano Chamizo L, Marciello M, Diaz-Sanchez M et al (2020) Multifunctional silica-based nanoparticles with controlled release of organotin metallodrug for targeted theranosis of breast cancer. Cancers (Basel) 12(1):187. https://doi.org/10.3390/cancers1201018710.3390/cancers12010187 ↗
34. Wang X, Ma Q, Wen C, Gong T, Li J, Liang W et al (2021) Folic acid and deoxycholic acid derivative modified Fe 3 O 4 nanoparticles for efficient pH-dependent drug release and multi-targeting against liver cancer cells. RSC Adv 11(63):39804–3981210.1039/D1RA05874F ↗
35. Gallo N, Nasser H, Salvatore L, Natali ML, Campa L, Mahmoud M et al (2019) Hyaluronic acid for advanced therapies: promises and challenges. Eur Polymer J 117:134–14710.1016/j.eurpolymj.2019.05.007 ↗
36. Spadea A, Rios de la Rosa JM, Tirella A, Ashford MB, Williams KJ, Stratford IJ et al (2019) Evaluating the efficiency of hyaluronic acid for tumor targeting via CD44. Molecular pharmaceutics 16(6):2481–9310.1021/acs.molpharmaceut.9b00083 ↗
37. Shi GY, Li ZT, Zhang ZC, Yin QQ, Li N, Wang SC et al (2023) Functionalized europium-doped hollow mesoporous silica nanospheres as a cell imaging and drug delivery agents. Biochem Biophys Res Commun 674:1–9. https://doi.org/10.1016/j.bbrc.2023.06.08210.1016/j.bbrc.2023.06.082 ↗
38. Charbgoo F, Taghdisi SM, Yazdian Li N, Wang SC, et al. Functionalized europium-doped hollow mesopor nanoparticle systems for drug delivery. Nanobiotechnology in Diagnosis, Drug Delivery, and Treatment. 2020:95–112.10.1002/9781119671732.ch5 ↗
39. Baranyai Z, Tircsó G, Rösch F (2020) The use of the macrocyclic chelator DOTA in radiochemical separations. Eur J Inorg Chem 2020(1):36–5610.1002/ejic.201900706 ↗
40. Wu H, Wei M, Xu Y, Li Y, Zhai X, Su P et al (2022) PDA-based drug delivery nanosystems: a potential approach for glioma treatment. Int J Nanomed 17:375110.2147/IJN.S378217 ↗
41. Fowler AM, Cho SY (2021) PET imaging for breast cancer. Radiol Clin North Am 59(5):725–735. https://doi.org/10.1016/j.rcl.2021.05.00410.1016/j.rcl.2021.05.004 ↗
42. Lebron L, Greenspan D, Pandit-Taskar N (2015) PET imaging of breast cancer: role in patient management. PET Clin 10(2):159–195. https://doi.org/10.1016/j.cpet.2014.12.00410.1016/j.cpet.2014.12.004 ↗
43. Fowler AM, Strigel RM (2022) Clinical advances in PET-MRI for breast cancer. Lancet Oncol 23(1):e32–e43. https://doi.org/10.1016/S1470-2045(21)00577-510.1016/S1470-2045(21)00577-5 ↗
44. Ming Y, Wu N, Qian T, Li X, Wan DQ, Li C et al (2020) Progress and future trends in PET/CT and PET/MRI molecular imaging approaches for breast cancer. Front Oncol 10:1301. https://doi.org/10.3389/fonc.2020.0130110.3389/fonc.2020.01301 ↗
45. Ferreira CA, Goel S, Ehlerding EB, Rosenkrans ZT, Jiang D, Sun T et al (2021) Ultrasmall porous silica nanoparticles with enhanced pharmacokinetics for cancer theranostics. Nano Lett 21(11):4692–4699. https://doi.org/10.1021/acs.nanolett.1c0089510.1021/acs.nanolett.1c00895 ↗
46. Hamid MTR, Ab Mumin N, Hamid SA, Saman MSA, Rahmat K (2024) Abbreviated breast magnetic resonance imaging (MRI) or digital breast tomosynthesis for breast cancer detection in dense breasts? A retrospective preliminary study with comparable results. Clin Radiol 79(4):e524–e531. https://doi.org/10.1016/j.crad.2023.12.01610.1016/j.crad.2023.12.016 ↗
47. Morrow M, Waters J, Morris E (2011) MRI for breast cancer screening, diagnosis, and treatment. Lancet 378(9805):1804–1811. https://doi.org/10.1016/S0140-6736(11)61350-010.1016/S0140-6736(11)61350-0 ↗
48. Gegios AR, Peterson MS, Fowler AM (2023) Breast cancer screening and diagnosis: recent advances in imaging and current limitations. PET Clin 18(4):459–471. https://doi.org/10.1016/j.cpet.2023.04.00310.1016/j.cpet.2023.04.003 ↗
49. Kadioglu ME, Metin Y, Metin NO, Tasci F, Ozdemir O, Kupeli A (2023) The efficacy of abbreviated breast MRI protocols using 1.5 T MRI in the preoperative staging of newly diagnosed breast cancers. Clin Imaging 101:44–9. https://doi.org/10.1016/j.clinimag.2023.05.01610.1016/j.clinimag.2023.05.016 ↗
50. Mann RM, Cho N, Moy L (2019) Breast MRI: state of the art. Radiology 292(3):520–53610.1148/radiol.2019182947 ↗
51. Zheng DW, Chen JL, Zhu JY, Rong L, Li B, Lei Q et al (2016) Highly integrated nano-platform for breaking the barrier between chemotherapy and immunotherapy. Nano Lett 16(7):4341–4347. https://doi.org/10.1021/acs.nanolett.6b0143210.1021/acs.nanolett.6b01432 ↗
52. Qiao H, Cui Z, Yang S, Ji D, Wang Y, Yang Y et al (2017) Targeting osteocytes to attenuate early breast cancer bone metastasis by theranostic upconversion nanoparticles with responsive plumbagin release. ACS Nano 11(7):7259–7273. https://doi.org/10.1021/acsnano.7b0319710.1021/acsnano.7b03197 ↗
53. Chan MH, Lin HM (2015) Preparation and identification of multifunctional mesoporous silica nanoparticles for in vitro and in vivo dual-mode imaging, theranostics, and targeted tracking. Biomaterials 46:149–158. https://doi.org/10.1016/j.biomaterials.2014.12.03410.1016/j.biomaterials.2014.12.034 ↗
54. Chen L, Zhou X, Nie W, Zhang Q, Wang W, Zhang Y et al (2016) Multifunctional redox-responsive mesoporous silica nanoparticles for efficient targeting drug delivery and magnetic resonance imaging. ACS Appl Mater Interfaces 8(49):33829–33841. https://doi.org/10.1021/acsami.6b1180210.1021/acsami.6b11802 ↗
55. Farjadian F, Faghih Z, Fakhimi M, Iranpour P, Mohammadi-Samani S, Doroudian M (2023) Glucosamine-modified mesoporous silica-coated magnetic nanoparticles: a “raisin-cake”-like structure as an efficient theranostic platform for targeted methotrexate delivery. Pharmaceutics 15(10):2491. https://doi.org/10.3390/pharmaceutics1510249110.3390/pharmaceutics15102491 ↗
56. El-Shahawy AAG, Zohery M, El-Dek SI (2022) Theranostics platform of Abemaciclib using magnetite@silica@chitosan nanocomposite. Int J Biol Macromol 221:634–643. https://doi.org/10.1016/j.ijbiomac.2022.09.02610.1016/j.ijbiomac.2022.09.026 ↗
57. Wan L, Chen Z, Deng Y, Liao T, Kuang Y, Liu J et al (2020) A novel intratumoral pH/redox-dual-responsive nanoplatform for cancer MR imaging and therapy. J Colloid Interface Sci 573:263–277. https://doi.org/10.1016/j.jcis.2020.04.02610.1016/j.jcis.2020.04.026 ↗
58. Rahman M (2023) Magnetic resonance imaging and iron-oxide nanoparticles in the era of personalized medicine. Nanotheranostics 7(4):42410.7150/ntno.86467 ↗
59. Sadegha S, Varshochian R, Dadras P, Hosseinzadeh H, Sakhtianchi R, Mirzaie ZH et al (2022) Mesoporous silica coated SPIONs containing curcumin and silymarin intended for breast cancer therapy. Daru 30(2):331–341. https://doi.org/10.1007/s40199-022-00453-910.1007/s40199-022-00453-9 ↗
60. Patil-Sen Y, Torino E, De Sarno F, Ponsiglione AM, Chhabria V, Ahmed W et al (2020) Biocompatible superparamagnetic core-shell nanoparticles for potential use in hyperthermia-enabled drug release and as an enhanced contrast agent. Nanotechnology 31(37):37510210.1088/1361-6528/ab91f6 ↗
61. Li N, Wang Z, Zhang Y, Zhang K, Xie J, Liu Y et al (2018) Curcumin-loaded redox-responsive mesoporous silica nanoparticles for targeted breast cancer therapy. Artif Cells Nanomed Biotechnol 46(sup2):921–935. https://doi.org/10.1080/21691401.2018.147341210.1080/21691401.2018.1473412 ↗
62. Tian HN, Zhang RF, Li JQ, Huang CL, Sun W, Hou ZQ et al (2022) A novel yolk-shell FeO@ mesoporous carbon nanoparticle as an effective tumor-targeting nanocarrier for improvement of chemotherapy and photothermal therapy. International Journal of Molecular Sciences 23(3):1623. https://doi.org/10.3390/ijms2303162310.3390/ijms23031623 ↗
63. Ting G, Chang C-H, Wang H-E (2009) Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy. Anticancer Res 29(10):4107–4118
64. Khalil MM, Tremoleda JL, Bayomy TB, Gsell W (2011) Molecular SPECT imaging: an overview. International journal of molecular imaging 2011(1):796025
65. Pratiwi FW, Kuo CW, Chen B-C, Chen P (2019) Recent advances in the use of fluorescent nanoparticles for bioimaging. Nanomedicine 14(13):1759–176910.2217/nnm-2019-0105 ↗
66. Ovejero-Paredes K, Diaz-Garcia D, Mena-Palomo I, Marciello M, Lozano-Chamizo L, Morato YL et al (2022) Synthesis of a theranostic platform based on fibrous silica nanoparticles for the enhanced treatment of triple-negative breast cancer promoted by a combination of chemotherapeutic agents. Biomater Adv 137:212823. https://doi.org/10.1016/j.bioadv.2022.21282310.1016/j.bioadv.2022.212823 ↗
67. Iorhemba MA, Alvarez-Conde J, Diaz-Garcia D, Mendez-Arriaga JM, Garcia-Almodovar V, Ovejero-Paredes K et al (2024) Vanadocene-functionalized mesoporous silica nanoparticles: platforms for the development of theranostic materials against breast cancer. Biomed Mater 19(3):035005. https://doi.org/10.1088/1748-605X/ad2c1c10.1088/1748-605X/ad2c1c ↗
68. Theodorou IG, Mpekris F, Papagiorgis P, Panagi M, Kalli M, Potamiti L, et al. Gold nanobipyramids for near-infrared fluorescence-enhanced imaging and treatment of triple-negative breast cancer. Cancers (Basel). 2023;15(14). https://doi.org/10.3390/cancers15143693.10.3390/cancers15143693 ↗
69. Kurz FT, Schlemmer H-P (2022) Imaging in translational cancer research. Cancer Biol Med 19(11):156510.20892/j.issn.2095-3941.2022.0677 ↗
70. Schmidt CW. CT scans: balancing health risks and medical benefits. National Institute of Environmental Health Sciences; 2012.10.1289/ehp.120-a118 ↗
71. Wang D, Xie W, Gao Q, Yan H, Zhang J, Lu J et al (2019) Non-magnetic injectable implant for magnetic field-driven thermochemotherapy and dual stimuli-responsive drug delivery: transformable liquid metal hybrid platform for cancer theranostics. Small 15(16):e1900511. https://doi.org/10.1002/smll.20190051110.1002/smll.201900511 ↗
72. Zhou W, Chen D, Li K, Yuan Z, Chen X (2023) Multimodal photoacoustic imaging in analytic vulnerability of atherosclerosis. iRADIOLOGY 1(4):303–1910.1002/ird3.39 ↗
73. Lin L, Wang LV (2022) The emerging role of photoacoustic imaging in clinical oncology. Nat Rev Clin Oncol 19(6):365–38410.1038/s41571-022-00615-3 ↗
74. Han R, Xiao Y, Yang Q, Pan M, Hao Y, He X et al (2021) Ag2S nanoparticle-mediated multiple ablations reinvigorates the immune response for enhanced cancer photo-immunotherapy. Biomaterials 264:12045110.1016/j.biomaterials.2020.120451 ↗
75. Nikam AN, Pandey A, Fernandes G, Kulkarni S, Mutalik SP, Padya BS et al (2020) Copper sulphide based heterogeneous nanoplatforms for multimodal therapy and imaging of cancer: recent advances and toxicological perspectives. Coord Chem Rev 419:21335610.1016/j.ccr.2020.213356 ↗
76. Yang W, Liang H, Ma S, Wang D, Huang J (2019) Gold nanoparticle based photothermal therapy: development and application for effective cancer treatment. Sustain Mater Technol 22:e00109
77. Wu JR, Bremner DH, Niu SW, Li DJ, Tang RR, Zhu LM (2019) Multifunctional A7R peptide-modified hollow mesoporous silica@AgS nanotheranostics for photoacoustic/near-infrared fluorescence imaging-guided tumor-targeted chemo-photothermal therapy. J Biomed Nanotechnol 15(7):1415–1431. https://doi.org/10.1166/jbn.2019.272910.1166/jbn.2019.2729 ↗
78. Xu C, Chen F, Valdovinos HF, Jiang D, Goel S, Yu B et al (2018) Bacteria-like mesoporous silica-coated gold nanorods for positron emission tomography and photoacoustic imaging-guided chemo-photothermal combined therapy. Biomaterials 165:56–65. https://doi.org/10.1016/j.biomaterials.2018.02.04310.1016/j.biomaterials.2018.02.043 ↗
79. Zhang W, Zhang CC, Wang XY, Li L, Chen QQ, Liu WW et al (2020) Light-responsive core-shell nanoplatform for bimodal imaging-guided photothermal therapy-primed cancer immunotherapy. ACS Appl Mater Interfaces 12(43):48420–48431. https://doi.org/10.1021/acsami.0c1652610.1021/acsami.0c16526 ↗
80. Liu N, Chen X, Sun X, Sun X, Shi J (2021) Persistent luminescence nanoparticles for cancer theranostics application. Journal of Nanobiotechnology 19:1–2410.1186/s12951-020-00755-7 ↗
81. Frasconi M, Liu Z, Lei J, Wu Y, Strekalova E, Malin D et al (2013) Photoexpulsion of surface-grafted ruthenium complexes and subsequent release of cytotoxic cargos to cancer cells from mesoporous silica nanoparticles. J Am Chem Soc 135(31):11603–11613. https://doi.org/10.1021/ja405058y10.1021/ja405058y ↗
82. Gao Y, Reig B, Heacock L, Bennett DL, Heller SL, Moy L (2020) Magnetic resonance imaging in screening of breast cancer. Radiol Clin North Am 59(1):8510.1016/j.rcl.2020.09.004 ↗
83. Chen F, Nayak TR, Goel S, Valdovinos HF, Hong H, Theuer CP et al (2014) In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol Pharm 11(11):4007–4014. https://doi.org/10.1021/mp500306k10.1021/mp500306k ↗
84. Zhang X, Xi Z, Machuki JO, Luo J, Yang D, Li J et al (2019) Gold cube-in-cube based oxygen nanogenerator: a theranostic nanoplatform for modulating tumor microenvironment for precise chemo-phototherapy and multimodal imaging. ACS Nano 13(5):5306–5325. https://doi.org/10.1021/acsnano.8b0978610.1021/acsnano.8b09786 ↗
85. Lee SB, Lee HW, Darmawan BA, Lee IK, Cho SJ, Chin J et al (2020) NIR dye-loaded mesoporous silica nanoparticles for a multifunctional theranostic platform: visualization of tumor and ischemic lesions, and performance of photothermal therapy. J Ind Eng Chem 88:99–105. https://doi.org/10.1016/j.jiec.2020.03.02710.1016/j.jiec.2020.03.027 ↗
86. Zhou J, Li M, Lim WQ, Luo Z, Phua SZF, Huo R et al (2018) A transferrin-conjugated hollow nanoplatform for redox-controlled and targeted chemotherapy of tumor with reduced inflammatory reactions. Theranostics 8(2):518–532. https://doi.org/10.7150/thno.2119410.7150/thno.21194 ↗
87. Gunaydin G, Gedik ME, Ayan S (2021) Photodynamic therapy for the treatment and diagnosis of cancer–a review of the current clinical status. Front Chem 9:68630310.3389/fchem.2021.686303 ↗
88. Kessel D (2020) Photodynamic therapy: apoptosis, paraptosis and beyond. Apoptosis 25(9):611–61510.1007/s10495-020-01634-0 ↗
89. Prieto D (2023) Photodynamic therapy: apoptosis, paraptosis and beyond. mesoporous silica nanoparticles combination for enhanced photodynamic therapy. Photochemistry and Photobiology 99(3):882–90010.1111/php.13802 ↗
90. Ma Q, Xiao J, Qiu Z, Huang H, Yan D, You Y et al (2024) Indocyanine green-loaded mesoporous silica nanocomposite for breast cancer imaging. ACS Applied Nano Materials 7(10):11377–1138510.1021/acsanm.4c00980 ↗
91. Zeng L, Pan Y, Zou R, Zhang J, Tian Y, Teng Z et al (2016) 808 nm-excited upconversion nanoprobes with low heating effect for targeted magnetic resonance imaging and high-efficacy photodynamic therapy in HER2-overexpressed breast cancer. Biomaterials 103(103):116–127. https://doi.org/10.1016/j.biomaterials.2016.06.03710.1016/j.biomaterials.2016.06.037 ↗
92. Su J, Sun H, Meng Q, Zhang P, Yin Q, Li Y (2017) Enhanced blood suspensibility and laser-activated tumor-specific drug release of theranostic mesoporous silica nanoparticles by functionalizing with erythrocyte membranes. Theranostics 7(3):523–537. https://doi.org/10.7150/thno.1725910.7150/thno.17259 ↗
93. Yang DZ, Yao XY, Dong JJ, Wang N, Du Y, Sun SA et al (2018) Design and investigation of core/shell GQDs/hMSN nanoparticles as an enhanced drug delivery platform in triple-negative breast cancer. Bioconjug Chem 29(8):2776–2785. https://doi.org/10.1021/acs.bioconjchem.8b0039910.1021/acs.bioconjchem.8b00399 ↗
94. Liu J, Zhao X, Nie W, Yang Y, Wu C, Liu W et al (2021) Tumor cell-activated “Sustainable ROS Generator” with homogeneous intratumoral distribution property for improved anti-tumor therapy. Theranostics 11(1):379–396. https://doi.org/10.7150/thno.5002810.7150/thno.50028 ↗
95. Huang W, Yu M, Sun S, Yu L, Wen S, Liu Y et al (2024) Mitochondrial-targeting nanotrapper captured copper ions to alleviate tumor hypoxia for amplified photoimmunotherapy in breast cancer. ACS Appl Mater Interfaces 16(2):2166–2179. https://doi.org/10.1021/acsami.3c1714610.1021/acsami.3c17146 ↗
96. Jain A, Koyani R, Munoz C, Sengar P, Contreras OE, Juarez P et al (2018) Magnetic-luminescent cerium-doped gadolinium aluminum garnet nanoparticles for simultaneous imaging and photodynamic therapy of cancer cells. J Colloid Interface Sci 526:220–229. https://doi.org/10.1016/j.jcis.2018.04.10010.1016/j.jcis.2018.04.100 ↗
97. Yang S, Pan H, George BP, Xuanjian F, Ma H, Cai X, et al. Bridging the gaps in photothermal therapy through the intersection of nanotechnology and cell membrane coating. Chemical Engineering Journal. 2024:149641.10.1016/j.cej.2024.149641 ↗
98. Norouzi H, Khoshgard K, Akbarzadeh F (2018) In vitro outlook of gold nanoparticles in photo-thermal therapy: a literature review. Lasers Med Sci 33:917–92610.1007/s10103-018-2467-z ↗
99. Gao G, Sun X, Liang G, Nanoagenteh F (2021) In vitro outlorature photothermal therapy for cancer treatment. Advanced Functional Materials 31(25):210073810.1002/adfm.202100738 ↗
100. Liu Y, Xu M, Chen Q, Guan GN, Hu W, Zhao XL et al (2015) Gold nanorods/mesoporous silica-based nanocomposite as theranostic agents for targeting near-infrared imaging and photothermal therapy induced with laser. Int J Nanomed 10:4747–4761. https://doi.org/10.2147/Ijn.S8294010.2147/Ijn.S82940 ↗